Anticoagulation Therapy in Children

Pediatric Drugs

Volumn 5, Issue 12, 2003, Pages 803-820

  Ronghe, Milind D ^a,b   Halsey, Christina ^b   Goulden, Nicholas J ^a  

^a BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^b ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTICOAGULANT AGENT; ANTITHROMBIN; ARDEPARIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; CEPHALOSPORIN DERIVATIVE; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PARNAPARIN; PENICILLIN DERIVATIVE; PROTEIN C; PROTEIN S; PROTHROMBIN; REVIPARIN; THROMBIN; THROMBOPLASTIN; TINZAPARIN; UNINDEXED DRUG; VITAMIN K GROUP; VON WILLEBRAND FACTOR; WARFARIN;

AGE; ALOPECIA; ANTICOAGULANT THERAPY; BLEEDING; CARBOXYLATION; CENTRAL VENOUS CATHETER; CHILDHOOD DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; HEMOSTASIS; HUMAN; INFERIOR CAVA VEIN; KIDNEY VEIN THROMBOSIS; LEG THROMBOSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RASH; REVIEW; RISK FACTOR; SKIN NECROSIS; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOPHILIA;

ADOLESCENT; ANTICOAGULANTS; CHILD; FACTOR XA; FEMALE; HALF-LIFE; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INFANT; MALE; RISK FACTORS; THROMBOEMBOLISM; WARFARIN;

EID: 0346158476     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200305120-00004     Document Type: Review

References (126)

1. Marsh D, Wilkerson S, Cook L, et al. Right atrial thrombus formation screening using two-dimensional echocardiograms in neonates with central venous catheters. Pediatrics 1988; 81: 284-6
2. Warner B, Gorgone P, Schilling S, et al. Multiple purpose central venous access in infants less than 1000 grams. J Pediatr Surg 1987; 22: 820-2
3. Andrew M, Marzinotto V, Pencharz P, et al. A cross-sectional study of catheter-related thrombosis in children receiving total parenteral nutrition at home. J Pediatr 1995; 126: 358-63
4. Beck C, Dubois J, Grignon A, et al. Incidence and risk factors of catheter related deep vein thrombosis in a pediatric intensive care unit: a prospective study. J Pediatr 1998; 133: 237-41
5. Andrew M, David M, Adams M, et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood 1994; 83 (5): 1251-7
6. van Ommen H, Heilboer H, Buller H, et al. Venous thromboembolisn in childhood: a prospective two-year registry in the Netherlands. J Pediatr 2001; 139 (5): 675-81
7. Nowak-Gottl U, von Kries R. Gobel U. Neonatal symptomatic thromboembolism in Germany: two year survey. Arch Dis Child Fetal Neonatal Ed 1997; 76 (3): 163F-7F
8. Boo N-Y, Wong N-C, Zulkifli SZ, et al. Risk factors associated with umbilical vascular catheter-associated thrombosis in newborn infants. J Pediatr Child Health 1999; 35: 460-5
9. Gurgey A, Aslan D. Outcome of non-catheter related thrombosis in children; influence of underlying or co-existing factors. J Pediatr Hematol Oncol 2001; 23 (3): 159-64
10. Bonduel M, Hepner M, Sciuccati G, et al. Prothrombotic abnormalities in children with venous thromboembolism. J Pediatr Hematol Oncol 2000; 22 (1): 66-72
11. Nowak-Gottl U, Kosch A, Schlegel N. Thromboembolism in newboms, infants and childen. Thromb Haemost 2001; 86: 464-74
12. Tormene D, Simioni P, Prandoni P, et al. The incidence of venous thromboembolism in thrombophilic children: a prospective cohort study. Blood 2002; 100 (7): 2403-5
13. Manco-Johnson M, Grabowski EF, Hellgreen M, et al. Laboratory testing for thrombophilia in pediatric patients. Thromb Haemost 2002; 88: 155-6
14. British Committee for Standards in Haematology. Guidelines on the insertion and management of central venous lines. Br J Haematol 1997; 98 (4): 1041-7
15. Monagle P, Adams M, Mahoney M, et al. Outcome of pediatric thromboembolic disease: a report from the Canadian Childhood Thrombophilia Registry. Pediatr Res 2000; 47 (6): 763-6
16. Hausler M, Hubner D, Delhaas T, et al. Long term complications of inferior vena cava thrombosis. Arch Dis Child 2001 ; 85 (3): 228-33
17. Schmidt B, Ofosu FA, Mitchell L, et al. Anticoagulant effects of heparin in neonatal plasma. Pediatr Res 1989; 25 (4): 405-8
18. Andrew M, Mitchell L, Vegh P, et al. Thrombin regulation in children differs from adults in the absence and presence of heparin. Thromb Haemost 1994; 72 (6): 836-42
19. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the full-term infant. Blood 1987; 70 (1): 165-72
20. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the healthy premature infant. Blood 1988; 72 (5): 1651-7
21. Andrew M, Paes B, Johnston M. Development of the hemostatic system in the neonate and young infant. Am J Pediatr Hematol Oncol 1990; 12 (1): 95-104
22. Shah JK, Mitchell LG, Paes B, et al. Thrombin inhibition is impaired in plasma of sick neonates. Pediatr Res 1992 Apr; 31 (4 Pt 1): 391-5
23. Duplaga BA, Rivers CW, Nutescu E. Dosing and monitoring of low-molecular-weight heparins in special populations. Pharmacotherapy 2001; 21 (2): 218-34
24. Hirsh J, Raschke R, Warkentin TE, et al. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995; 108 (4 Suppl.): 258S-75S
25. Hirsh J, Warkentin TE, Raschke R, et al. Heparin and low-molecular- weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998; 114 (5 Suppl.): 489S-510S
26. Rosenberg RD, Bauer KA. The heparin-antithrombin system: a natural anticoagulant mechanism. In: Colman RW, Hirsh J, Marder VJ, et al., editors. Hemostasis and thrombosis: basic principles and clinical practice. 3rd ed. Philadelphia (PA): JB Lippincott, 1994: 837-60
27. Lam LH, Silbert JE. Rosenberg RD. The separation of active and inactive forms of heparin. Biochem Biophys Res Commun 1976; 69 (2): 570-7
28. Andersson LO, Barrowcliffe TW, Holmer E, et al. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin iii and by gel filtration. Thromb Res 1976; 9 (6): 575-83
29. Tollefsen DM, Majerus DW, Blank MK. Heparin cofactor II: purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J Biol Chem 1982 Mar; 257 (5): 2162-9
30. Casu B, Oreste P, Torri G, et al. The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin III-binding sequence: chemical and 13C nuclear-magnetic- resonance studies. Biochem J 1981 Sep; 197 (3): 599-609
31. Lindahl U, Thunberg L, Backstrom G, et al. Extension and structural variability of the anithrombin-binding sequence in heparin. J Biol Chem 1984 Oct; 259 (20): 12368-76
32. Lane DA, Denton J, Flynn AM, et al. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J 1984 Mar; 218 (3): 725-32
33. Oosta GM, Gardner WT, Beeler DL, et al. Multiple functional domains of the heparin molecule. Proc Natl Acad Sci U S A 1981; 78 (2): 829-33
34. Sobel M, McNeill PM, Carlson PL, et al. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J Clin Invest 1991 May; 87 (5): 1787-93
35. Blajchman MA, Young E, Ofosu FA. Effects of unfractionated heparin, dermatan sulfate and low molecular weight heparin on vessel wall permeability in rabbits. Ann N Y Acad Sci 1989; 556: 245-54
36. Fernandez F, N'guyen P, Van Ryn J, et al. Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. Thromb Res 1986 Aug; 43 (4): 491-5
37. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986; 315 (18): 1109-14
38. Clowes AW, Karnowsky MJ. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 1977; 265 (5595): 625-6
39. Bhandari M, Hirsh J, Weitz JI, et al. The effects of standard and low molecular weight heparin on bone nodule formation in vitro. Thromb Haemost 1998; 80 (3): 413-7
40. de Swart CA, Nijmeyer B, Roelofs JM, et al. Kinetics of intravenously administered heparin in normal humans. Blood 1982; 60 (6): 1251-8
41. Bjornsson TD. Dose-dependent decrease in heparin elimination. J Pharm Sci 1982 Oct; 71 (10): 1186-8
42. Hirsh J, van Aken WG, Gallus AS, et al. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation 1976; 53 (4): 691-5
43. Young E, Prins M, Levine MN, et al. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost 1992; 67 (6): 639-43
44. Andrew M, Marzinotto V, Massicotte P, et al. Heparin therapy in pediatric patients: a prospective cohort study. Pediatr Res 1994; 35 (1): 78-83
45. Michelson AD, Bovill E, Monagle P, et al. Antithrombotic therapy in children. Chest 1998; 114: 748S-69S
46. British Committee tor Standards in Haematology guidelines. The use and monitoring of heparin. J Clin Pathol 1993; 46: 97-103
47. Hirsh J. Drug therapy: heparin. N Engl J Med 1991; 324 (22): 1565-74
48. Carr ME, Carr SL. At high heparin concentrations, protamine concentrations which reverse heparin anticoagulant effects are insufficient to reverse heparin antiplatelet effects. Thromb Res 1994 Sep 15; 75 (6): 617-30
49. Sackler JP, Liu L. Heparin-induced osteoporosis. Br J Radiol 1973 Jul; 46 (547): 548-50
50. Murphy MS, John PR, Mayer AD, et al. Heparin therapy and bone fractures [letter]. Lancet 1992 Oct; 340 (8827): 1098
51. Avioli LV. Heparin-induced osteopenia: an appraisal. Adv Exp Med Biol 1975; 52: 375-87
52. Murdoch IA, Beattie RM, Silver DM. Heparin-induced thrombocytopenia in children. Acta Paediatr 1993; 82 (5): 495-7
53. Spadone D, Clark F, James E, et al. Heparin-induced thrombocytopenia in the newborn. J Vasc Surg 1992; 15 (2): 306-12
54. Wilhelm MJ, Schmid C, Kececioglu D, et al. Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia using Org 10172. Ann Thorac Surg 1996; 61 (3): 920-4
55. Potter C, Cox Gill J, Scott JP, et al. Heparin-induced thrombocytopenia in a child. J Pediatr 1992; 121 (1): 135-8
56. Klement D, Rammos S, Kries VR, et al. Heparin as a cause of thrombus progression: heparin-associated thrombocytopenia is an important differential diagnosis in paediatric patients even with normal platelet counts. Eur J Pediatr 1996; 155 (1): 11-4
57. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost 1993; 70 (4): 554-61
58. Alving BM, Krishnamurti C. Recognition and management of heparin-induced thrombocytopenia (HIT) and thrombosis. Semin Thromb Hemost 1997; 23 (6): 569-74
59. Chong BH, Eisbacher M. Pathophysiology and laboratory testing of heparin-induced thrombocytopenia. Semin Hematol 1998; 35 (4 Suppl. 5): 3-8
60. Tardy B, Page Y, Tardy-Poncet B, et al. Low-molecular weight heparin induced thrombocytopenia [letter]. Therapie 1990; 45 (5): 453
61. De Raucourt E, Vinsonneau C, Juvin K, et al. Heparin-induced thrombocytopenia with thrombotic complications during prophylactic treatment with low-molecular-weight heparin. Blood Coagul Fibrinolysis 1996; 7 (8): 786-8
62. Illuminati G, Calio FG, Bertagni A, et al. Heparin induced thrombocytopenia after low molecular weight heparin treatment: a case report. Riv Eur Sci Med Farmacol 1996; 18 (5-6): 225-8
63. Warkentin TE. Heparin-induced thrombocytopenia: a ten-year retrospective. Annu Rev Med 1999; 50: 129-47
64. Warkentin TE, Greinacher A, editors. Heparin-induced thrombocytopenia. New York (NY): Marcel Dekker, 2000
65. Zohrer B, Zenz W, Rettenbacher A, et al. Danaparoid sodium (Orgaran) in four children with heparin-induced thrombocytopenia type II. Acta Pediatr 2001; 90: 765-71
66. Salzman E, Rosenberg R, Smith M, et al. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980; 65: 64-73
67. Massicotte P, Adams M, Marzinotto V, et al. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr 1996; 128(3): 313-8
68. Massicotte MP, Adams M, Leaker M, et al. A nomogram to establish therapeutic levels of the low molecular weight heparin (LMWH), clivarine in children requiring treatment for venous thromboembolism (VTE) [abstract]. Thromb Haemost 1997; Suppl.: 282
69. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79 (1): 1-17
70. Van Ryn-McKenna J, Cai L, Ofosu FA, et al. Neutralization of enoxaparine-induced bleeding by protamine sulfate. Thromb Haemost 1990; 63 (2): 271-4
71. Massonnet-Castel S, Pelissier E, Bara L, et al. Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation. Haemostasis 1986; 16(2): 139-46
72. Andrew M, de Veber G. Pediatric thromboembolism and stroke protocols. Hamilton (BC), Canada: Decker, 1997
73. Public Health Service. Invasive procedures in pediatric patients on low molecular weight heparin. Rockville (MD): US Food and Drug Administration, 1997
74. van der Heijden JF, Prins MH, Buller HR. Low-molecular-weight heparins: are they interchangeable? Haemostasis 2000; 30 Suppl. 2: 148-57
75. Duxbury BM, Poller L. The oral anticoagulant saga: past, present, and future. Clin Appl Thromb Hemost 2001; 7 (4): 269-75
76. Whitlon DS, Sadowski JA, Suttie JW. Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition. Biochemistry 1978 Apr; 17 (8): 1371-7
77. Fasco MJ, Hildebrandt EF, Suttie JW. Evidence that warfarin anticoagulant action involves two distinct reductase activities. J Biol Chem 1982 Oct; 257 (19): 11210-2
78. Choonara IA, Malia RG, Haynes BP, et al. The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin. Br J Clin Pharmacol 1988 Jan; 25 (1): 1-7
79. Nelsestuen GL. Role of gamma-carboxyglutamic acid: an unusual protein transition required for the calcium-dependent binding of prothrombin to phospholipid. J Biol Chem 1976 Sep; 251 (18): 5648-56
80. Borowski M, Furie BC, Bauminger S, et al. Prothrombin requires two sequential metal-dependent conformational transitions to bind phospholipid: conformation-specific antibodies directed against the phospholipid-binding site on prothrombin. J Biol Chem 1986 Nov; 261 (32): 14969-75
81. Friedman PA, Rosenberg RD, Hauschka PV, et al. A spectrum of partially carboxylated prothrombins in the plasmas of coumarin-treated patients. Biochim Biophys Acta 1977 Sep; 494 (1): 271-6
82. Kelly JG, O'Malley K. Clinical pharmacokinetics of oral anticoagulants. Clin Pharmacokinet 1979 Jan-Feb; 4 (1): 1-15
83. O'Reilly RA. Vitamin K and the oral anticoagulant drugs. Annu Rev Med 1976; 27: 245-61
84. O'Reilly RA. Warfarin metabolism and drug interactions. In Wessler S, Becker CG, Nemerson Y, editors. The new dimensions of warafarin prphylaxis advances in experimental medicine and biology. New York: Perseus Publishing, 1986: 205-12
85. Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353 (9154): 717-9
86. Mannucci PM. Genetic control of anticoagulation. Lancet 1999; 353 (9154): 688-9
87. O'Reilly RA, Pool JG, Aggeler PM. Hereditary resistance to coumarin anticoagulant drugs in man and rat. Ann N Y Acad Sci 1968 Jul; 151 (2): 913-31
88. Alving BM, Strickler MP, Knight RD, et al. Hereditary warfarin resistance: investigation of a rare phenomenon. Arch Intern Med 1985 Mar; 145 (3): 499-501
89. Sadowski JA, Booth SL, Mann KG, et al. Structure and mechanism of activation of vitamin K antagonists. In: Poller L, Hirsh J. editors. Oral anticoagulants. London, UK: Arnold, 1996: 9-29
90. O'Reilly RA, Rytand DA. 'Resistance' to warfarin due to unrecognized vitamin K supplementation. N Engl J Med 1980 Jul; 303 (3): 160-1
91. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119: 8S-21S
92. Schmidt B, Andrew M. Report of scientific and standardization subcommittee on neonatal hemostasis diagnosis and treatment of neonatal thrombosis. Thromb Haemost 1992 Mar; 67 (3): 381-2
93. Massicotte P, Leaker M, Marzinotto V, et al. Enhanced thrombin regulation during warfarin therapy in children compared to adults. Thromb Haemost 1998 Oct; 80 (4): 570-4
94. Wessler S, Gitel SN. Warfarin: from bedside to bench. N Engl J Med 1984 Sep; 311 (10): 645-52
95. Zivelin A, Rao LV, Rapaport SI. Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors. J Clin Invest 1993 Nov; 92 (5): 2131-40
96. Patel P, Weitz J, Brooker LA, et al. Decreased thrombin activity of fibrin clots prepared in cord plasma compared with adult plasma. Pediatr Res 1996 May; 39 (5): 826-30
97. Furie B, Diuguid CF, Jacobs M, et al. Randomized prospective trial comparing the native prothrombin antigen with the prothrombin time for monitoring oral anticoagulant therapy. Blood 1990; 75 (2): 344-9
98. Harrison L, Johnston M, Massicotte MP, et al. Comparison of 5mg and 10mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997; 126 (2): 133-6
99. Quick AJ. The prothrombin time in hemophilia and in obstructive jaundice. J Biol Chem 1935; 109: 73-4
100. Andrew M, Marzinotto V, Brooker LA, et al. Oral anticoagulation therapy in pediatric patients: a prospective study. Thromb Haemost 1994; 71 (3): 265-9
101. Streif W, Andrew M, Marzinotto V, et al. Analysis of warfarin therapy in pediatric patients: a prospective cohort study of 319 patients. Blood 1999; 94 (9): 3007-14
102. Bradley LM, Midgley FM, Watson DC, et al. Anticoagulation therapy in children with mechanical prosthetic cardiac valves. Am J Cardiol 1985 Sep; 56 (8): 533-5
103. Carpentieri U, Nghiem QX, Harris LC. Clinical experience with an oral anticoagulant in children. Arch Dis Child 1976 Jun; 51 (6): 445-8
104. Woods A, Vargas J, Berri G, et al. Antithrombotic therapy in children and adolescents. Thromb Res 1986 May; 42 (3): 289-301
105. Doyle JJ, Koren G, Cheng MY, et al. Anticoagulation with sodium warfarin in children: effect of a loading regimen. J Pediatr 1988; 113 (6): 1095-7
106. Hathaway W, Corrigan J. Report of scientific and standardization subcommittee on neonatal hemostasis: normal coagulation data for fetuses and newborn infants. Thromb Haemost 1991; 65 (3): 323-5
107. Tait RC, Ladusans EJ, El-Mrtaal M, et al. Oral anticoagulation in paediatric patients: dose requirements and complications. Thromb Haemost 1996; 74: 228-31
108. Hull R, Delmore T, Genton E, et al. Warfarin sodium versus low-dose heparin the long-term treatment of venous thrombosis. N Engl J Med 1979 Oct; 301 (16): 855-8
109. Nowak-Gottl U, Kosch A, Schlegel N, et al. Thromboembolism in children. Curr Opin Hematol 2002; 9: 448-53
110. Hull R, Delmore T, Carter C, et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 1982 Jan; 306 (4): 189-94
111. Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism: Duration of Anticoagulation Trial Study Group. N Engl J Med 1995; 332 (25); 1661-5
112. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy: Duration of Anticoagulation Study Group. Am J Med 1998 Apr; 104 (4): 332-8
113. Nowak-Gottl U, Junker R, Kreuz W, et al. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood 2001; 97 (4): 858-62
114. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. [published erratum appears in N Engl J Med 1999 Jul 22; 341 (4): 298]. N Engl J Med 1999 Mar 25; 340 (12): 901-7
115. Eichinger S, Minar E, Hirschl M, et al. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb Haemost 1999 Jan; 81 (1): 14-7
116. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1998; 114 (5 Suppl.); 445S-69S
117. Monagle P, Michelson AD, Bovill E, et al. Antithrombotic therapy in children. Chest 2001; 119: 344S-70S
118. Guidelines on oral anticoagulation: third edition. Br J Haematol 1998; 101: 374-87
119. Landefeld S, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction and prevention. Am J Med 1993; 95: 315-28
120. Fihn SD, McDonnell M, Martin D, et al. Risk factors for complications of chronic anticoagulation: a multicenter study. Ann Intern Med 1993; 118: 511-20
121. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996; 348: 423-8
122. Hylek EM, Singer D. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120: 897-902
123. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997; 42: 857-65
124. Maillard C, Berruyer M, Serre CM, et al. protein S, a vitamin K dependent protein is a bone matrix component synthesized and secreted by osteoblasts. Endocrinology 1997; 130: 1599-604
125. Massicote P, Julian J, Webber C, et al. Osteoporosis: a potential complication of long term warfarin therapy [abstract]. Thromb Haemost 1999; Suppl: 1333a
126. Sawicki PT. A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. JAMA 1999; 281 (2): 145-50